Neon Therapeutics Inc (NASDAQ:NTGN) saw unusually-high trading volume on Monday . Approximately 1,056,675 shares traded hands during trading, an increase of 612% from the previous session’s volume of 148,430 shares.The stock last traded at $4.62 and had previously closed at $4.32.
NTGN has been the topic of a number of research analyst reports. Mizuho set a $21.00 target price on Neon Therapeutics and gave the stock a “buy” rating in a research report on Monday, July 1st. Berenberg Bank decreased their target price on Lucara Diamond from C$1.60 to C$1.50 in a research report on Wednesday, March 27th. Zacks Investment Research upgraded Booz Allen Hamilton from a “hold” rating to a “buy” rating and set a $71.00 target price on the stock in a research report on Friday, June 28th. Finally, HC Wainwright began coverage on Neon Therapeutics in a research report on Thursday, May 30th. They issued a “buy” rating and a $10.00 price objective on the stock. One research analyst has rated the stock with a hold rating and eight have given a buy rating to the company’s stock. The stock currently has an average rating of “Buy” and a consensus target price of $16.89.
The company has a debt-to-equity ratio of 0.09, a current ratio of 7.30 and a quick ratio of 7.30. The company’s 50-day simple moving average is $4.75. The company has a market cap of $130.89 million and a price-to-earnings ratio of -0.83.
Neon Therapeutics (NASDAQ:NTGN) last issued its quarterly earnings data on Monday, May 13th. The company reported ($0.76) earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.73) by ($0.03). On average, research analysts predict that Neon Therapeutics Inc will post -2.67 EPS for the current year.
A number of institutional investors have recently added to or reduced their stakes in the stock. Marshall Wace North America L.P. purchased a new stake in shares of Neon Therapeutics during the first quarter worth $49,000. Acadian Asset Management LLC bought a new position in Neon Therapeutics during the first quarter valued at about $268,000. Rhumbline Advisers bought a new position in Neon Therapeutics during the first quarter valued at about $78,000. Oppenheimer & Co. Inc. bought a new position in Neon Therapeutics during the first quarter valued at about $194,000. Finally, Harel Insurance Investments & Financial Services Ltd. raised its holdings in Neon Therapeutics by 100.0% during the first quarter. Harel Insurance Investments & Financial Services Ltd. now owns 10,000 shares of the company’s stock valued at $65,000 after buying an additional 5,000 shares in the last quarter. Hedge funds and other institutional investors own 69.57% of the company’s stock.
Neon Therapeutics Company Profile (NASDAQ:NTGN)
Neon Therapeutics, Inc, a clinical-stage immuno-oncology company, engages in developing neoantigen-targeted therapies for cancers in the United States. It is developing NEO-PV-01, a neoantigen vaccine that is in Phase Ib clinical trial in combination with nivolumab for the treatment of metastatic melanoma, non-small cell lung cancer, and bladder cancer; NEO-PTC-01, a neoantigen T cell therapy for the treatment of solid tumors; and NEO-SV-01, a neoantigen vaccine for the treatment of estrogen-receptor-positive breast cancer.
Recommended Story: How does a security become overbought?
Receive News & Ratings for Neon Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Neon Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.